Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Related to this article
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Advertisement
Advertisement
Trending on AJMC
1
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
2
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
3
Expert Panel Updates Consensus on Mantle Cell Lymphoma Care Using Pan-Asian Data
4
One-Size Dialysis Volume Goals Fall Short in CKD: Jennifer Flythe, MD
5